ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1923

An Evaluation of Costs Associated with Overall and Renal-Specific Organ Damage in Patients with Systemic Lupus Erythematosus in the United States

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Bell, Christopher F., GlaxoSmithKline, Research Triangle, North Carolina, United States
  • Meyers, Juliana, RTI Health Solutions, Research Triangle Park, North Carolina, United States
  • Ajmera, Mayank, RTI Health Solutions, Research Triangle Park, North Carolina, United States
  • Wu, Benjamin, GlaxoSmithKline, Research Triangle, North Carolina, United States
  • Von Feldt, Joan, GlaxoSmithKline, Philadelphia, Pennsylvania, United States
Background

Systemic lupus erythematosus (SLE) is a chronic, multisystem, inflammatory, autoimmune disease affecting multiple organ systems, and characterized by fluctuating disease activity (flares). The combination of flares and SLE treatment toxicity increases the risk of organ damage (OD), including renal OD. Despite the high prevalence of OD and the associated poor disease prognosis, real-world studies on the economic impact of OD, especially renal OD, in SLE are limited.

Methods

This retrospective analysis (GSK Study 208380) used the IQVIA PharMetrics Plus Database to identify patients with SLE and OD during 01/01/09–06/30/18. Patients with OD were identified using International Classification of Diseases (ICD)-9/10 codes derived from the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.1 Inclusion criteria: ≥18 years of age; continuous enrollment 12 months both pre and post index (index: date of first observed OD medical claim); ≥1 inpatient (IP) or ≥3 outpatient (OP) claims within 6 months for an OD-related diagnosis code; ≥1 IP or ≥2 OP claims separated by ≥30 days for SLE (ICD-9: 710.0 or ICD-10: M32.X) prior to the OD index date. Patients with renal-specific OD at index were noted. Patient characteristics were identified in the 12-month pre-index period and all-cause healthcare costs (2018 US$) were reported in the 12-month pre- and post-index periods. Results were analyzed with descriptive statistics.

Results

A total of 8952 patients met OD criteria and 486 (5.4%) had renal-specific OD. Patients were 92% female, mean (standard deviation [SD]) age was 46.4 (12.2) years, and mean (SD) Charlson Comorbidity Index was 2.0 (1.1). Mean (SD) all-cause healthcare costs increased from $15,746 ($29,637) to $26,998 ($57,982) in pre- versus post-index periods, respectively. In patients with renal-specific OD, mean (SD) all-cause healthcare costs increased from $16,131 ($22,914) to $36,905 ($72,188) in pre- versus post-index periods, respectively.

Conclusion

In patients with SLE and OD, annual costs increased after OD diagnosis. A similar increase in annual costs was observed for patients with renal-specific OD at index.

1Gladman DD and Urowitz MB. Lupus. 1999;8:632–7.

Funding

  • Commercial Support